Published in J Neuroimmunol on April 01, 1995
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 2.55
The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1. J Cell Biol (1999) 1.79
Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol (2008) 1.52
Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there. Crit Rev Immunol (2009) 1.49
The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin. J Clin Invest (1998) 1.49
Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS (2011) 1.21
Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b. J Clin Invest (1997) 1.15
Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clin Cancer Res (2012) 1.14
Structural specializations of α(4)β(7), an integrin that mediates rolling adhesion. J Cell Biol (2012) 1.13
beta2-integrins in demyelinating disease: not adhering to the paradigm. J Leukoc Biol (2009) 1.03
Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol (2010) 1.02
alpha4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions. J Neuroimmunol (2009) 0.96
How natalizumab binds and antagonizes α4 integrins. J Biol Chem (2013) 0.95
SAP suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. Immunol Cell Biol (2011) 0.92
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics (2013) 0.92
The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front Immunol (2013) 0.91
Modulation of the expression of integrins on glial cells during experimental autoimmune encephalomyelitis. A central role for TNF-alpha. Am J Pathol (1997) 0.88
CD44 is involved in selective leucocyte extravasation during inflammatory central nervous system disease. Immunology (1999) 0.87
Developing therapeutics for the treatment of multiple sclerosis. NeuroRx (2005) 0.83
Disruption of the beta2-integrin CD11d (alphaDbeta2) gene fails to protect against experimental autoimmune encephalomyelitis. J Neuroimmunol (2007) 0.82
Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis. J Neuroimmunol (2012) 0.81
Managing MS in a changing treatment landscape. J Neurol (2011) 0.79
Monoclonal antibodies as disease modifying therapy in multiple sclerosis. Curr Neurol Neurosci Rep (2013) 0.79
Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin. J Immunol (2011) 0.78
Dose-dependent anti-inflammatory and neuroprotective effects of an ανβ3 integrin-binding peptide. Mediators Inflamm (2013) 0.78
Anti-inflammatory activity of c(ILDV-NH(CH2)5CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion. Br J Pharmacol (1999) 0.78
Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC. J Clin Immunol (2007) 0.78
The novel α4B murine α4 integrin protein splicing variant inhibits α4 protein-dependent cell adhesion. J Biol Chem (2014) 0.76
Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab. Clinicoecon Outcomes Res (2009) 0.75
Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study. PLoS One (2013) 0.75
Integrins as Therapeutic Targets: Successes and Cancers. Cancers (Basel) (2017) 0.75
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature (1992) 7.20
Characterization of human prorenin expressed in mammalian cells from cloned cDNA. Proc Natl Acad Sci U S A (1986) 3.60
In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci U S A (1996) 3.53
Cloning of a lymphocyte homing receptor reveals a lectin domain. Cell (1989) 3.33
Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci U S A (1988) 2.95
In situ immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system. Cell Death Differ (1998) 2.48
A cell culture model of the blood-brain barrier. J Cell Biol (1991) 2.35
Exocytosis regulates urinary acidification in turtle bladder by rapid insertion of H+ pumps into the luminal membrane. Proc Natl Acad Sci U S A (1982) 2.28
Fas-induced activation of the cell death-related protease CPP32 Is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem (1996) 2.26
Receptors involved in lymphocyte homing: relationship between a carbohydrate-binding receptor and the MEL-14 antigen. J Cell Biol (1987) 2.13
Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J Biol Chem (1997) 1.97
Early interventions in severe sepsis and septic shock: a review of the evidence one decade later. Minerva Anestesiol (2012) 1.96
The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II. Nature (1989) 1.94
Involvement of sialic acid on endothelial cells in organ-specific lymphocyte recirculation. Science (1985) 1.85
Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature (1993) 1.85
The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. J Biol Chem (1990) 1.83
Messenger RNA coding for only the alpha subunit of the rat brain Na channel is sufficient for expression of functional channels in Xenopus oocytes. Proc Natl Acad Sci U S A (1986) 1.79
Bax- and Bak-induced cell death in the fission yeast Schizosaccharomyces pombe. Mol Biol Cell (1997) 1.75
Phosphomannosyl-derivatized beads detect a receptor involved in lymphocyte homing. J Cell Biol (1987) 1.64
Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins. J Biol Chem (1997) 1.58
Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. Transplantation (1999) 1.56
Homing receptors on human and rodent lymphocytes--evidence for a conserved carbohydrate-binding specificity. Blood (1987) 1.51
Peptide inhibitors of the ICE protease family arrest programmed cell death of motoneurons in vivo and in vitro. Neuron (1995) 1.46
Interaction of aluminum species with deoxyribonucleic acid. Biochemistry (1980) 1.39
GlyCAM-1, a physiologic ligand for L-selectin, activates beta 2 integrins on naive peripheral lymphocytes. J Exp Med (1996) 1.39
T-lymphocyte subsets in acute illness. Crit Care Med (1995) 1.39
Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells. J Biol Chem (1998) 1.38
Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Magn Reson Imaging (2000) 1.37
Alpha 4 beta 1 integrin-dependent cell adhesion is regulated by a low affinity receptor pool that is conformationally responsive to ligand. J Biol Chem (1995) 1.33
Structural and functional complementation of an inactive Bcl-2 mutant by Bax truncation. J Biol Chem (1997) 1.32
First observation of the Greisen-Zatsepin-Kuzmin suppression. Phys Rev Lett (2008) 1.29
A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members. J Biol Chem (1997) 1.24
Identification and cloning of two species of cadherins in bovine endothelial cells. EMBO J (1990) 1.23
Intravenously injected sialidase inactivates attachment sites for lymphocytes on high endothelial venules. J Immunol (1989) 1.21
Characterization and biological effects of recombinant human erythropoietin. Immunobiology (1986) 1.20
Activation of the CED3/ICE-related protease CPP32 in cerebellar granule neurons undergoing apoptosis but not necrosis. J Neurosci (1997) 1.19
VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE. J Neuroimmunol (2009) 1.15
Avermectin B1a irreversibly blocks postsynaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance. Proc Natl Acad Sci U S A (1979) 1.13
Glucocorticoids inhibit glucose transport and glutamate uptake in hippocampal astrocytes: implications for glucocorticoid neurotoxicity. J Neurochem (1991) 1.12
Structure-function analysis of the integrin beta 7 subunit: identification of domains involved in adhesion to MAdCAM-1. J Immunol (1997) 1.10
Isolation and characterization of a monoclonal antibody against the saxitoxin-binding component from the electric organ of the eel Electrophorus electricus. Proc Natl Acad Sci U S A (1982) 1.10
Regulation of conformation and ligand binding function of integrin alpha5beta1 by the beta1 cytoplasmic domain. J Biol Chem (1996) 1.08
In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor. Infect Immun (1988) 1.07
Direct suppression of natural killer activity in human peripheral blood leukocyte cultures by glucocorticoids and its modulation by interferon. Cancer Res (1983) 1.07
A role of chondroitin sulfate glycosaminoglycan binding site in alpha4beta1 integrin-mediated melanoma cell adhesion. J Biol Chem (1998) 1.06
DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J Virol (1998) 1.01
Carbon-dioxide-induced exocytotic insertion of H+ pumps in turtle-bladder luminal membrane: role of cell pH and calcium. Nature (1985) 1.01
Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene (2013) 1.01
Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies (1997) 1.00
Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock. Mol Med (1999) 1.00
Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Ann Neurol (1992) 0.99
VEGF and vascular changes in chronic neuroinflammation. J Autoimmun (2003) 0.98
Activation of membrane-associated procaspase-3 is regulated by Bcl-2. J Cell Biol (1999) 0.98
Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol (1999) 0.97
Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: evaluations of 108 chemicals. Environ Mol Mutagen (1987) 0.96
Endothelial selectins and alpha4 integrins regulate independent pathways of T lymphocyte recruitment in the pulmonary immune response. J Immunol (1998) 0.96
The effect of synaptic activation on the extracellular potassium concentration in the hippocampal dentate area, in vitro. Brain Res (1976) 0.96
Irreversible caspase inhibitors: tools for studying apoptosis. Methods (1999) 0.95
Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J Virol (2000) 0.95
Studies on the mechanism of action of avermectin B1a: stimulation of release of gamma-aminobutyric acid from brain synaptosomes. J Neurochem (1980) 0.94
Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol (1996) 0.93
Role of the adrenal cortex in gastric mucosal protection by prostaglandins, sulfhydryls, and cimetidine in the rat. Gastroenterology (1983) 0.93
Computer-assisted identification and quantification of multiple sclerosis lesions in MR imaging volumes in the brain. J Magn Reson Imaging (1994) 0.92
Immunological evidence that inactive renin is prorenin. Biochem Biophys Res Commun (1985) 0.91
Differentiation of brain endothelial cells in cell culture. Ann N Y Acad Sci (1991) 0.91
Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of alpha4 integrin. J Neuroimmunol (2002) 0.90
Immunochemical properties and cytochemical localization of the voltage-sensitive sodium channel from the electroplax of the eel (Electrophorus electricus). J Neurosci (1983) 0.90
The failed appointment. J Okla State Med Assoc (1991) 0.87
Human renin is correctly processed and targeted to the regulated secretory pathway in mouse pituitary AtT-20 cells. J Biol Chem (1987) 0.87
Computational blood flow modeling based on in vivo measurements. Ann Biomed Eng (1999) 0.87
In vivo treatment with anti-alpha4 integrin suppresses clinical and pathological evidence of Borna disease virus infection. J Neuroimmunol (1998) 0.87
Differential regulation of beta1 integrins by chemoattractants regulates neutrophil migration through fibrin. J Cell Biol (1999) 0.86
Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay. J Neurochem (1991) 0.86
Differentiation of parenchymal lung disorders with in vitro proton nuclear magnetic resonance. Magn Reson Med (1986) 0.85
Comparative efficiency of feline immunodeficiency virus infection by DNA inoculation. AIDS Res Hum Retroviruses (1997) 0.84
An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology (1993) 0.84
NMR studies in experimental allergic encephalomyelitis (EAE): normalization of T1 and T2 with parenchymal cellular infiltration. Neurology (1986) 0.84
Connexin 43 gap junction proteins are up-regulated in remyelinating spinal cord. J Neurosci Res (2007) 0.84
The effect of diamide on transmitter release and on synaptic vesicle population at vertebrate synapses. Brain Res (1981) 0.84
The beta-amyloid precursor protein is not processed by the regulated secretory pathway. Biochem Biophys Res Commun (1991) 0.83
Isolation and culture of HCO3- -secreting intercalated cells. Am J Physiol (1989) 0.83
Expression and functional significance of an activation-dependent epitope of the beta 1 integrins in chronic inflammatory diseases. Eur J Immunol (1995) 0.82
Indications of proton-dominated cosmic-ray composition above 1.6 EeV. Phys Rev Lett (2010) 0.82
NMR changes in experimental allergic encephalomyelitis: NMR changes precede clinical and pathological events. Magn Reson Med (1987) 0.82
In vivo measurements of multi-component T2 relaxation behaviour in guinea pig brain. Magn Reson Imaging (1999) 0.81
Two RFLPs at the human renin (ren) gene locus. Nucleic Acids Res (1986) 0.81
Lobster neuromuscular junctions treated with black widow spider venom: correlation between ultrastructure and physiology. J Neurocytol (1980) 0.81
Experimental allergic encephalomyelitis in connexin 43-heterozygous mice. Cell Commun Adhes (2007) 0.81
Different components of black widow spider venom mediate transmitter release at vertebrate and lobster neuromuscular junctions. Nature (1980) 0.81
Effect of educational programs, rigid sharps containers, and universal precautions on reported needlestick injuries in healthcare workers. Infect Control Hosp Epidemiol (1991) 0.80
Pathogenesis of experimental adrenal hemorrhagic necrosis ("apoplexy"): ultrastructural, biochemical, neuropharmacologic, and blood coagulation studies with acrylonitrile in the rat. Lab Invest (1980) 0.80